Aspects concerning patient adherence to anti‑TNFα therapy in psoriasis: A decade of clinical experience
- Madalina Mocanu
- Mihaela‑Paula Toader
- Elena Rezus
- Tatiana Taranu
Affiliations: Dermatology Clinic, Railways University Hospital Iasi, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700506 Iasi, Romania, Rheumatology Clinic, University Rehabilitation Hospital, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
- Published online on: September 16, 2019 https://doi.org/10.3892/etm.2019.8008
Copyright: © Mocanu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Non‑adherence to psoriasis treatment has an important impact in controlling chronic disease evolution and the occurrence of systemic comorbidities. Biologic therapy represents a revolutionary treatment, many of the undesirable psychological and socio‑economical consequences of conventional topical or systemic therapies being avoided. Nevertheless, the discontinuation of biological therapy may occur due to facts related to the patient, to the lack of good communication between the patient and the physician or to the adverse or paradoxical reactions. We studied the non‑adherence reasons to anti‑TNFα agents (Infliximab, Adalimumab, Etanercept) used for treating 84 cases with moderate‑severe psoriasis. The results of our study over the past 10 years showed a 76.2% adherence rate, lowest in patients treated with Etanercept (70.9%). Relative to the anti‑TNF agent used, the highest adherence rate was recorded in Adalimumab (80.8%), followed by Infliximab (76.5%) and Etanercept (70.9%). We have noticed differences between the rates of adhesion to therapy with different anti‑TNFα agents, but with no statistical significance. The main adverse effects that occurred during anti‑TNFα therapy were: local reaction to the drug, mild infectious events, allergic reactions, cardiotoxicity, alopecia areata, pancreatitis, eosinophilia, thrombocytopenia. Anti‑TNF therapy was discontinued in one case of endocarditis, one case with tuberculous laryngitis and another one with polydiscitis (Adalimumab), a case of colon cancer and one of pregnancy (Etanercept) and one paradoxical reaction (Infliximab).